112734-22-2

Usage

Chemical Properties

Clear colorless to slightly yellow liquid

InChI:InChI:1S/C7H7BrFN/c8-6-2-1-5(4-10)7(9)3-6/h1-3H,4,10H2

Upstream product

• 105942-08-3 4-bromo-6-fluorobenzonitrile 

Downstream Products

• 112733-66-1 2-Amino-N-(4-bromo-2-fluorobenzyl)benzamide 
• 158460-92-5 [3-(4-Bromo-2-fluoro-benzyl)-2,4-dioxo-3,4-dihydro-2H-thieno[3,2-d]pyrimidin-1-yl]-acetic acid ethyl ester 
• 122185-97-1 ethyl 3-(4-bromo-2-fluorobenzyl)-2,4-dioxo-6-phenylthieno<2,3-d>pyrimidin-1-acetate 
• 129688-70-6 2-[(4-Bromo-2-fluorophenyl)methyl]-1,2,3,4-tetrahydro-1,3-dioxo-4-isoquinoline-carboxylic Acid Methyl Ester 
• 1025813-05-1 2-[3-(4-Bromo-2-fluoro-benzyl)-ureido]-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid ethyl ester 
• 1028278-92-3 2-[3-(4-Bromo-2-fluoro-benzyl)-ureido]-4-methyl-thiophene-3-carboxylic acid ethyl ester 
• 1028264-38-1 2-[3-(4-Bromo-2-fluoro-benzyl)-ureido]-5-methyl-thiophene-3-carboxylic acid ethyl ester 
• 1026561-43-2 3-[3-(4-Bromo-2-fluoro-benzyl)-ureido]-benzo[b]thiophene-2-carboxylic acid methyl ester 
• 1025809-12-4 3-[3-(4-Bromo-2-fluoro-benzyl)-ureido]-4-chloro-benzo[b]thiophene-2-carboxylic acid methyl ester 
• 1026839-30-4 3-[3-(4-Bromo-2-fluoro-benzyl)-ureido]-6-chloro-benzo[b]thiophene-2-carboxylic acid methyl ester 
• 147254-64-6 ranirestat 
• 314297-97-7 3-(4-bromo-2-fluoro-benzyl)-7-methoxy benzo[e][1,3]oxazine-2,4-dione 
• 314297-95-5 N-(4-bromo-2-fluoro-benzyl)-4-chloro-2-hydroxy-benzamide 
• 1029715-38-5 N'-(4-bromo-2-fluorobenzyl)-N,N-dimethylurea 

Relevant academic research and scientific papers

SULFONYL-SUBSTITUTED BENZOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF

The present invention relates to a sulfonyl-substituted benzoheterocyclic derivative, a preparation method and medical use thereof. Particularly, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a preparation method and application thereof. The definition of each group in the formula can be found in the specification and the claims.

NOVEL ANTIBIOTICS AND METHODS OF USING SAME

The present invention includes novel 3,6-diazabicyclo[3.1.1]heptane antibiotic compounds and any salts or solvates thereof. The present invention further includes methods of preparing such compounds, and methods of treating bacterial infection in a subjec

COMPOUNDS USEFUL AS KINASE INHIBITORS

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

Reductions of aliphatic and aromatic nitriles to primary amines with diisopropylaminoborane

Diisopropylaminoborane [BH2Nf)Pr)2] in the presence of a catalytic amount of lithium borohydride (LiBH4) reduces a large variety of aliphatic and aromatic nitriles in excellent yields. BH 2NOPr)2 can be prepared by two methods: first by reacting diisopropylamineborane [(iPr)2N)BH3] with 1.1 equiv of n-butylhthium (n-BuLi) followed by methyl iodide (MeI), or reacting iPrN:BH 3 with 1 equiv of n-BuLi followed by trimethylsilyl chloride (TMSCl). BH2N(ZPr)2 prepared with MeI was found to reduce benzonitriles to the corresponding benzylamines at ambient temperatures, whereas diisopropylaminoborane prepared with TMSCl does not reduce nitriles unless a catalytic amount of a lithium ion source, such as LiBH4 or lithium tetraphenylborate (LiBPh4), is added to the reaction. The reductions of benzonitriles with one or more electron-withdrawing groups on the aromatic ring generally occur much faster with higher yields. For example, 2,4-dichlorobenzonitrile was successfully reduced to 2,4-dichlorobenzylamine in 99% yield after 5 h at 25 °C. On the other hand, benzonitriles containing electron-donating groups on the aromatic ring require refluxing in tetrahydrofuran (THF) for complete reduction. For instance, 4- methoxybenzonitrile was successfully reduced to 4-methoxybenzylamine in 80% yield. Aliphatic nitriles can also be reduced by the BH2N(iPr) 2/cat. LiBH4 reducing system. Benzyl cyanide was reduced to phenethylamine in 83% yield. BH2NOPr)2 can also reduce nitriles in the presence of unconjugated alkenes and alkynes such as the reduction of 2-hexynenitrile to hex-5-yn-l-amine in 80% yield. Unfortunately, selective reduction of a nitrile in the presence of an aldehyde is not possible as aldehydes are reduced along with the nitrile. However, selective reduction of the nitrile group at 25 °C in the presence of an ester is possible as long as the nitrile group is activated by an electron-withdrawing substituent. It should be pointed out that lithium aminoborohydrides (LABs) do not reduce nitriles under ambient conditions and behave as bases with aliphatic nitriles as well as nitriles containing acidic a-protons. Consequently, both LABs and BH2NOPr)2 are complementary to each other and offer methods for the selective reductions of multifunctional compounds.

Lithium aminoborohydrides 16. Synthesis and reactions of monomeric and dimeric aminoboranes

(Chemical Equation Presented) Aminoboranes are synthesized in situ from the reaction of the corresponding lithium aminoborohydrides (LABs) with methyl iodide, trimethylsilylchloride (TMS-Cl), or benzyl chloride under ambient conditions. In hexanes, the reaction using methyl iodide produces aminoborane and methane, whereas in tetrahydrofuran (THF) this reaction produces amine-boranes (R1R2HN:BH3) as the major product. The reaction of iPr-LAB with TMS-Cl or benzyl chloride yields exclusively diisopropylaminoborane [BH2-N(iPr)2] in THF as well as in hexanes at 25°C. Diisopropylaminoborane and dicyclohexylaminoborane exist as monomers due to the steric requirement of the alkyl group. All other aminoboranes studied are not sterically hindered enough to be monomers in solution, but instead exist as a mixture of monomers and dimers. The dimers are four-membered rings formed through boron-nitrogen coordination. In general aminoboranes are not hydroborating reagents. However, monomelic aminoboranes, such as BH2-N(iPr)2, can reduce nitriles in the presence of catalytic amounts of LiBH4. This BH 2-N(iPr)2/LiBH4 reducing system also reduces ketones, aldehydes, and esters. Diisopropylaminoborane, synthesized from iPr-LAB, can be converted into boronic acids by a palladium-catalyzed reaction with aryl bromides. Aminoboranes derived from heterocyclic amines, such as pyrrole, pyrazole, and imidazole, can be prepared by the direct reaction of borane/tetrahydrofuran (BH3:THF) with these heterocyclic amines. It has been reported that pyrazole-derived aminoborane forms a six-membered dimer through boron-nitrogen coordination, where as, pyrrolylborane forms a dimer through boron-hydrogen coordination. Pyrrolylborane monohydroborates both alkenes and alkynes at ambient temperatures. Hydroboration of styrene with pyrrolylborane followed by hydrolysis gives the corresponding boronic acid, 2-phenylethylboronic acid, in 40% yield. Similarly phenylacetylene is mono-hydroborated by pyrrolylborane, to give E-2-phenylethenylboronic acid in 50% yield.

Methods and fluorinated compositions for treating amyloid-related diseases

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing amyloid-related disease.